Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 43,212	$ 62,478
Short-term restricted cash	540	1,034
Prepaid expenses and other current assets	2,093	6,344
Refundable tax credit	244	1,276
Total current assets	46,089	71,132
Operating lease right-of-use assets	2,360	3,331
Other assets	389	507
Total assets	48,838	74,970
Current liabilities:
Current portion of debt	222	208
Accounts payable	1,733	1,495
Accrued expenses	4,267	9,066
Operating lease liabilities — current	899	1,751
Total current liabilities	7,121	12,520
Debt, net of current portion	117	168
Operating lease liabilities	1,786	2,395
Other liabilities	0	16
Total liabilities	9,024	15,099
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value: 100,000,000 shares authorized; 18,999,701 and 18,266,545 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	19	18
Additional paid-in capital	276,551	267,018
Accumulated deficit	(237,698)	(208,654)
Accumulated other comprehensive income	274	165
Total stockholders’ equity attributable to Millendo Therapeutics, Inc.	39,146	58,547
Equity attributable to noncontrolling interests	668	1,324
Total stockholders’ equity	39,814	59,871
Total liabilities and stockholders’ equity	$ 48,838	$ 74,970